The rise of GLP-1 medications is not just transforming how much Americans eat, it’s reshaping what they choose to eat. New data from CookUnity, the chef-led meal delivery platform connecting eaters ...

Oral weight-loss medications could widen demand, but the bigger issue is whether coverage is becoming a must-have benefit or ...

A growing body of research suggests that GLP-1 drugs do more than control appetite and blood sugar. They could also fight ...

Originally developed for Type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the weight-loss medication market. And in recent years, their popularity has soared due to ...

There is no shortage of headlines about GLP-1 medications. Originally developed to manage blood sugar levels, these medications are now widely known for promoting weight loss. Alongside their rapid ...

The U.S. Food and Drug Administration (FDA) recently approved Eli Lilly and Company’s oral GLP-1 receptor agonist, Foundayo (orforglipron), ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...

Experts describe the development of oral GLP-1 medication as a “pivotal” improvement in the accessibility and adherence to obesity drugs. As of February 2026, only Wegovy and Rybelsus are available in ...

Recent research and clinical updates highlight how GLP-1 receptor agonists are transforming diabetes and obesity care, with expanding uses from adolescents with type 2 diabetes to off-label ...

The blockbuster GLP-1 drugs that have reshaped the treatment of diabetes and obesity may help prevent multiple substance use disorders — and reduce the tragic outcomes they cause, a large new study ...

ColonBroom is taking a more targeted approach. The company has launched an upgraded version of its GLP-1 Premium formula, ...